• Explore /
  • Poster
  • / A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).

A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).

Abstract Poster

Authors

null

Hirokazu Shoji

Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Hirokazu Shoji , Satoru Iwasa , Aya Kuchiba , Gakuto Ogawa , Mamiko Kawasaki , Kenichi Nakamura , Mikio Mori , Yoshitaka Honma , Atsuo Takashima , Ken Kato , Narikazu Boku , Natsuko Okita , Yasuhide Yamada

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

UMIN000023446

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3538)

DOI

10.1200/JCO.2019.37.15_suppl.3538

Abstract #

3538

Poster Bd #

30

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Gastrointestinal Cancers Symposium

A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).

A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).

First Author: Ardaman Shergill

First Author: Nieves Martinez Lago

First Author: Jiwon Lee

First Author: Takanori Watanabe